Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company's proprietary perinatal tissue-derived cell therapy for chronic lower back pain associated with degenerative disc disease.

The study produced statistically significant, clinically meaningful improvements in both functional disability (ODI%) and pain at primary trial end point, confirming durable human efficacy alongside an excellent safety profile.

The announcement of this data follows a previously announced study enrollment completion and positive independentData Safety Monitoring Board (DSMB) safety review, which confirmed that CELZ-201(Olastrocel) demonstrated a favorable safety profile with no significant adverse events and supported continued advancement of the trial.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.